Search

EROL KİRESEPİ ADDRESSES B20 – TURKEY DIALOGUE

Mr Erol Kiresepi, Co-Chair of B20 Employment & Education Task Force, says “The employment cause resulted from COVID-19 pandemic is estimated to be equivalent to 255 million full-time jobs in 2020.”

Mr Erol Kiresepi, Chairman of Santa Farma İlaç Sanayii, Deputy Chairman of Union of Chemical Petroleum Rubber and Plastic Industry Employers of Turkey (KİPLAS), IOE Honorary President and Co-Chair of B20 Employment & Education Task Force, addressed “B20 – Turkey Dialogue” webinar organized jointly by TÜSİAD and B20 Italian Presidency.

“B20 – Turkey Dialogue” webinar was organized by  TÜSİAD and B20 Italian Presidency on September 23, 2021 with a view to informing Turkish business world about the fundamental results of the activities performed prior to B2 Summit and improving the interaction between the business world and G20.

Mr Raci Kaya, Turkey’s G20 Sherpa, was the keynote speaker of the meeting which started with the opening speeches uttered by Mr Simone Kaslowski, Chairman of TÜSİAD and Member of B20 International Advisory Board, and Ms Emma Marcegaglia, B20 President.

Mr Erol Kiresepi, Chairman of Santa Farma İlaç Sanayii, Deputy Chairman of KİPLAS, Honorary President of International Organisation of Employers (IOE) and Co-Chair of B20 Employment & Education Task Force, Mr Levent Çakıroğlu Koç Holding’ CEO and Co-Chair of B20 Trade & Investment Task Force, Mr Simone Mori, Co-Chair of B20 Energy & Resource Efficiency Task Force, and Mr Roberto Scrivo, Co-Chair of B20 Digital Transformation Task Force, made a number policy suggestions as well as other important suggestions on climate change and empowerment of women, which are among the priorities of B20 International Advisory Board.




B20 Employment & Education Task Force Issues 3 Recommendations to G20

Mr Erol Kiresepi, Co-Chair of B20 Employment & Education Task Force, referred to the devastating impact of COVID-19 pandemic on labour markets in his address and noted that the employment cause resulted from the pandemic is estimated to be equivalent to 255 million full-time jobs in 2020 according to the data provided by the International Labour Organisation (ILO), which is around four times more than the job loss caused by the Global Financial Crisis in 2008. Mr Kiresepe also made reference to the important activities conducted for improving the relationship between labour markets and education throughout his four years’ term at IOE, comprised of more than 50 million companies in 145 countries, and shared the recommendations of B20 with the participants.

Underlining that B20 strongly recommends G20 countries to ensure acquisition of workforce skills required for future industrial revolutions, Kiresepi explained that the second recommendation of B20 is related to improving labour market policies and regulatory frameworks with a view to promoting productivity and growth. Finally, Erol Kiresepi mentioned the third recommendation which is related to adoption of measures to increase employment for the youth and women and reducing black economy.

Mr Kiresepi concluded his speech by underlining that the implementation of those recommendations will be critical in the upcoming period and assured the participants that B20 will continue to support G20 and G20 members in education and employment as the representative of the business world.


In the final section, B20 International Advisory Board Member Zeynep Bodur Okyay communicated the assessments of the business world as to “Women’s Empowerment and Combating Climate Change” which are among the priorities of B20 International Advisory Board.

Intended to be presented to G20 leaders, B20 suggestions shall be disclosed to the public at B20 Summit which will be held in Rome on October 7-8.


About Santa Farma


Santa Farma, marking its 75th anniversary as one of the most deep-rooted pharmaceutical companies in Turkey, was incorporated in 1944 as Farma Laboratory to manufacture pesticides, cough drops and syrup and other simple but widely used medicines. The foundation of current Santa Farma was laid following merger with Santa Laboratory in 1946. The company decided to establish a manufacturing plant in 1953. Santa Farma İlaç Fabrikası Kollektif Şirketi was incorporated in 1954, followed with the establishment of Santa Farma İlaç Sanayi A.Ş. in 1973. Santa Farma operates in 9 distinct therapeutic categories with totally 66 products supplied to 48 different markets. The therapeutic categories are Dermatology, Digestive System and Metabolism, Gastroenterology and Infection, Hematology, Cardiovascular System, Musculoskelatal System, Nervous System (MSS) and Respiratory System. The manufacturing plant of the company which has an indoor area of 44,000 sqm in GEBKİM OIZ boasts of a manufacturing capacity of annually 150 million boxes.


For detailed information, please visit our corporate website on www.santafarma.com.tr.


About KİPLAS


Established in 1961, the Union of Chemical Petroleum Rubber and Plastic Industry Employers of Turkey (KİPLAS) is an organisation of employers. It has 79 members operating on various fields including chemicals, rubber, plastic, paint, petrochemicals, and composites. KİPLAS primarily offers Industrial Relations and Technical Training-Consulting services. The “Legal and Social Relations Department” offers legal guidance training services including collective labour agreements and litigations with a view to providing guidance on individual labour relations and human resources management on fields of industrial relations. The “Technical and Training Department”, on the other hand, conducts training, guidance and independent site audit services regarding workplace safety, environment, classification, labelling and transportation of chemicals in line with the local and international laws and regulations, and industrial risks (technical safety, fire safety). Please visit www.kiplas.org.tr for detailed information.


 



Are you a health professional?

If you are not a health professionals we advice you to go back and visit some other page of our web site. Please confirm that you are a health professional or select "no" to go back.

Yes No